pyrazines has been researched along with clopidogrel in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushi, H; Imura, Y; Kawamura, M; Kita, S; Moriya, N; Nishikawa, K; Sugihara, H; Terashita, Z | 1 |
| Axelsen, LN; Bruderer, S; Perez Ruixo, JJ; Poggesi, I; Rasschaert, F | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Namiki, N; Odagiri, K; Tanaka, S; Tatsumi, K; Uchida, S; Watanabe, H | 1 |
3 other study(ies) available for pyrazines and clopidogrel
| Article | Year |
|---|---|
Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Topics: Alprostadil; Animals; Arginine; Aspirin; Clopidogrel; Dogs; Fibrinolytic Agents; Guanidines; Guinea Pigs; Humans; Macaca fascicularis; Male; Pipecolic Acids; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines; Sulfonamides; Ticlopidine | 1996 |
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
Topics: Acetamides; Clopidogrel; Cytochrome P-450 CYP2C8; Drug Interactions; Healthy Volunteers; Humans; Male; Pyrazines | 2021 |
Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
Topics: Acetamides; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Japan; Pharmaceutical Preparations; Pyrazines | 2021 |